BH3:FRA
PTC Therapeutics, Inc.
€55.34
arrow_downward
-1.57%(-0.88) 1D
Oct 8, 8:03:01 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
€55.34
High
€55.34
Low
€55.34
Mkt. cap
5.22B
Avg. vol.
0.00
Volume
0.00
52-wk high
€77.02
52-wk low
€52.50
No. of employees
991
Open
€55.34
High
€55.34
Low
€55.34
Mkt. cap
5.22B
Avg. vol.
0.00
Volume
0.00
52-wk high
€77.02
52-wk low
€52.50
No. of employees
991
News stories
From web sources and news partners
Yahoo Finance
·
15 hours ago
PTC Therapeutics, Inc. (PTCT) Stock Forecasts
MarketBeat
·
19 hours ago
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock
Investing.com
·
20 hours ago
PTC Therapeutics CLO Mark Boulding sells $132,790 in shares
Stock Titan
·
21 hours ago
Under a trading plan, PTC Therapeutics (PTCT) CLO sells 1,638 shares, then 435 more.
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com